Artelo Biosciences Reports Positive ART26.12 Pain Data
SOLANA BEACH, Calif., July 1, 2026 Artelo Biosciences, Inc. announced positive preclinical data demonstrating that its investigational drug candidate...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOLANA BEACH, Calif., July 1, 2026 Artelo Biosciences, Inc. announced positive preclinical data demonstrating that its investigational drug candidate...
SAN DIEGO, Calif., July 2, 2026 Arcturus Therapeutics Holdings Inc. announced a strategic collaboration with Thermo Fisher Scientific to...
ZURICH, Switzerland, July 2, 2026 VERAXA Biotech AG announced the initiation of cell line development for its lead BiTAC®...
SAN DIEGO, June 30, 2026 Contineum Therapeutics, Inc. announced the publication of its scientific manuscript describing the discovery and...
TOKYO, June 29, 2026 Daiichi Sankyo and AstraZeneca have announced that the European Commission (EC) has approved Enhertu® (trastuzumab...
TOKYO, June 29, 2026 Eisai Co., Ltd. has announced it will present more than 50 scientific presentations highlighting the...
LANSING, Mich. and BOSTON, Mass., June 16, 2026 Niowave, Inc. and Ratio Therapeutics Inc. have entered into a strategic...
VANCOUVER, British Columbia, June 16, 2026 Optimi Health Corp. has announced the commercial production of two new standardized microdose...
STOCKHOLM, Sweden, June 13, 2026 Johnson & Johnson has announced groundbreaking results from the pivotal Phase 3 MonumenTAL-3 clinical...
BOSTON, Mass., June 11, 2026 JW Pharmaceutical announced new preclinical findings and its global development strategy for DDC-02, an...
